Craig Vine, MD
Psychiatry · St Paul, MNNPI 1164400495
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $96,240 of the $136,362 with a category attached, or 70.6%. 19 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 52.6% of the total. Reporting peaked in 2022 at $39,606 and has fallen 98.9% since, to $439 in 2025. Among psychiatry clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $466.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$72K
- Alkermes, Inc.$43K
- Otsuka America Pharmaceutical, Inc.$14K
- Johnson & Johnson$5K
- Neuronetics, Inc.$1K
- Livanova USA, Inc.$1K
- plus $537 from 13 others
What the payments were for
- Consulting fees$23,09617%
- Speaking & faculty fees$96,24071%
- Travel & lodging$10,9688%
- Food & beverage$6,0584%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 109 | $71,724 |
| Alkermes, Inc. | 60 | $42,632 |
| Otsuka America Pharmaceutical, Inc. | 39 | $14,052 |
| Johnson & Johnson | 23 | $5,046 |
| Neuronetics, Inc. | 16 | $1,262 |
| Livanova USA, Inc. | 13 | $1,109 |
| Tempus AI, Inc | 2 | $114 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $91 |
| Lundbeck LLC | 4 | $63 |
| Vanda Pharmaceuticals Inc. | 3 | $43 |
| Corium, LLC | 4 | $41 |
| Almatica Pharma LLC | 3 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Eisai Inc. | 2 | $32 |
| AbbVie(2 entities) | 2 | $23 |
| Tris Pharma Inc | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$167,450
- INGREZZA$70,135
- ABILIFY MAINTENA$13,382
- SPRAVATO$4,603
- VNS Therapy Symmetry Model 8103 Generator$654
- NEUROSTAR TMS THERAPY SYSTEM$576
- NEUROSTAR TMS THERAPY$215
- VNS - Symmetry$112
How this compares
$136,362 in reported general payments places this provider in the 95th percentile of 552 psychiatry providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 37 | $326,959 |
| RexultiBrexpiprazole | 91 | $154,893 |
| TrintellixVortioxetine Hydrobromide | 85 | $36,280 |
| ClozarilClozapine | 13 | $35,967 |
| VraylarCariprazine Hcl | 18 | $31,905 |
| CaplytaLumateperone Tosylate | 17 | $26,938 |
| FetzimaLevomilnacipran Hcl | 47 | $26,463 |
| SeroquelQuetiapine Fumarate | 16 | $22,532 |
| Seroquel XrQuetiapine Fumarate | 17 | $22,300 |
| AuvelityDextromethorphan Hbr/Bupropion | 19 | $21,268 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $19,418 |
| Effexor XrVenlafaxine Hcl | 15 | $14,784 |
| Aripiprazole | 293 | $14,014 |
| Vilazodone Hcl | 144 | $11,720 |
| SunosiSolriamfetol Hcl | 11 | $9,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $71,724 | $326,95937 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $14,052 | $154,89391 claims |
| AbbVieVraylar, Fetzima | $23 | $58,36865 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $33 | $43,076103 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $91 | $26,93817 claims |
| Alkermes, Inc.Lybalvi | $42,632 | $19,41812 claims |
| Eisai Inc.Dayvigo | $32 | $3,59011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 552 psychiatry providers in Minnesota.
Other psychiatry in St Paul
- Sujit VarmaEdina$581K
- Michael FarnsworthMankato$548K
- Danielle Magness-WellmannMankato$232K
- Thomas WinegardenChanhassen$55K
- John LuehrMinnetonka$41K
- Walter RushSaint Paul$41K
- John SimonMinneapolis$32K
- Ziad NahasMinneapolis$32K
- Sophia VinogradovMinneapolis$25K
- Daniel MontvilleRochester$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.